Pfizer Aims For More Regional Research Partnerships

BMI Core View: Collaborations between pharmaceutical companies, contract research organisations (CROs), academia, non-profit organisations and governments will become increasingly important in accelerating research and development (R&D). The primary benefit of such partnerships is to spread the risks associated with drug

To read the full article, please choose one of the following options: